Previous 10 | Next 10 |
2024-02-21 09:42:51 ET Major earnings expected before the bell on Thursday include: Dominion Energy ( D ) Iron Mountain ( IRM ) Moderna ( MRNA ) Newmont ( NEM ) Nikola ( NKLA ) Read the full article on Seeking Alpha For further details...
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the Italian Medicine Agency (A...
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference...
2024-01-21 22:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...
2024-01-04 10:48:31 ET More on Rhythm Pharmaceuticals Rhythm Pharmaceuticals: Major Catalysts Due For Weight Loss Specialist Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2023 Earnings Call Transcript Rhythm Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentati...
2024-01-04 09:51:10 ET More on Rhythm Pharmaceuticals Rhythm Pharmaceuticals: Major Catalysts Due For Weight Loss Specialist Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2023 Earnings Call Transcript Rhythm Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentati...
-- LB54640 has shown targeted effect on MC4 receptor without hyperpigmentation -- -- Rhythm to advance LB54640 in two Phase 2 clinical trials -- BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company...
-- Phase 3 hypothalamic obesity top-line data expected in 1H2025 -- -- Positive reimbursement decision achieved for IMCIVREE ® (setmelanotide) to treat patients with Bardet-Biedl syndrome and POMC/LEPR deficiencies in Spain -- -- IND application for RM-7...
2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...
News, Short Squeeze, Breakout and More Instantly...
Rhythm Pharmaceuticals Inc. Company Name:
RYTM Stock Symbol:
NASDAQ Market:
Rhythm Pharmaceuticals Inc. Website:
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rar...
2024-06-14 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- Participants from the completed Phase 2 hypothalamic obesity trial reported positive changes in sleep, energy levels during setmelanotide therapy in qualitative interviews - - Separate analysis of patients across MC4R pathway diseases showed one year of treatment with setmelanotide im...